| Dr David Kee Tom, MD | |
|
13203 N 103rd Ave Ste H5, Sun City, AZ 85351-3032 | |
| (623) 777-4747 | |
| Not Available |
| Full Name | Dr David Kee Tom |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 24 Years |
| Location | 13203 N 103rd Ave Ste H5, Sun City, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043491988 | NPI | - | NPPES |
| 52007 | Medicaid | AZ |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novaspine Pain Institute Plc | 9931323359 | 20 |
News Archive
Guided Therapeutics, Inc., developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that, after a series of meetings with the U.S. Food and Drug Administration (FDA), and after reviewing draft responses, the FDA has asked the company to provide additional information in the company's response to one remaining question.
A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease.
Texas Gov. Rick Perry, who recently underwent an experimental injection of his own adult stem cells to relieve back pain, pushed a bill through the Legislature in June that paves the way for a company co-owned by his doctor to become the first state-approved "bank" to store and cultivate such cells for medical treatment that fact illustrates two aspects of his record that are drawing increasing attention as he pursues the presidency: his enthusiasm for ideas that are sometimes outside the scientific mainstream and what critics view as his willingness to use the levers of state government to benefit friends and political benefactors.
New estimates from the World Health Organization highlight need for increased, sustained investment in the development of mental health services in areas affected by conflict.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
› Verified 1 days ago
| Entity Name | Integrated Anesthesia Consultants Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144645656 PECOS PAC ID: 2264664549 Enrollment ID: O20140421001511 |
News Archive
Guided Therapeutics, Inc., developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that, after a series of meetings with the U.S. Food and Drug Administration (FDA), and after reviewing draft responses, the FDA has asked the company to provide additional information in the company's response to one remaining question.
A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease.
Texas Gov. Rick Perry, who recently underwent an experimental injection of his own adult stem cells to relieve back pain, pushed a bill through the Legislature in June that paves the way for a company co-owned by his doctor to become the first state-approved "bank" to store and cultivate such cells for medical treatment that fact illustrates two aspects of his record that are drawing increasing attention as he pursues the presidency: his enthusiasm for ideas that are sometimes outside the scientific mainstream and what critics view as his willingness to use the levers of state government to benefit friends and political benefactors.
New estimates from the World Health Organization highlight need for increased, sustained investment in the development of mental health services in areas affected by conflict.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
› Verified 1 days ago
| Entity Name | Novaspine Pain Institute Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154745263 PECOS PAC ID: 9931323359 Enrollment ID: O20140630000941 |
News Archive
Guided Therapeutics, Inc., developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that, after a series of meetings with the U.S. Food and Drug Administration (FDA), and after reviewing draft responses, the FDA has asked the company to provide additional information in the company's response to one remaining question.
A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease.
Texas Gov. Rick Perry, who recently underwent an experimental injection of his own adult stem cells to relieve back pain, pushed a bill through the Legislature in June that paves the way for a company co-owned by his doctor to become the first state-approved "bank" to store and cultivate such cells for medical treatment that fact illustrates two aspects of his record that are drawing increasing attention as he pursues the presidency: his enthusiasm for ideas that are sometimes outside the scientific mainstream and what critics view as his willingness to use the levers of state government to benefit friends and political benefactors.
New estimates from the World Health Organization highlight need for increased, sustained investment in the development of mental health services in areas affected by conflict.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Kee Tom, MD Po Box 5068, Sun City West, AZ 85376 Ph: (623) 777-4747 | Dr David Kee Tom, MD 13203 N 103rd Ave Ste H5, Sun City, AZ 85351-3032 Ph: (623) 777-4747 |
News Archive
Guided Therapeutics, Inc., developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that, after a series of meetings with the U.S. Food and Drug Administration (FDA), and after reviewing draft responses, the FDA has asked the company to provide additional information in the company's response to one remaining question.
A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease.
Texas Gov. Rick Perry, who recently underwent an experimental injection of his own adult stem cells to relieve back pain, pushed a bill through the Legislature in June that paves the way for a company co-owned by his doctor to become the first state-approved "bank" to store and cultivate such cells for medical treatment that fact illustrates two aspects of his record that are drawing increasing attention as he pursues the presidency: his enthusiasm for ideas that are sometimes outside the scientific mainstream and what critics view as his willingness to use the levers of state government to benefit friends and political benefactors.
New estimates from the World Health Organization highlight need for increased, sustained investment in the development of mental health services in areas affected by conflict.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
› Verified 1 days ago
Otto Uhrik, MD Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 10228 W Coggins Dr, Suite 1, Sun City, AZ 85351 Phone: 623-214-8800 Fax: 623-214-3446 |